2025年7月31日，新天药业(002873.SZ)发布2025年半年度报告。截至2025年7月30日，共有6个机构投资 者披露持有新天药业A股股份，合计持股量达8180.79万股，占新天药业总股本的33.51%。其中，机构 投资者包括上海新天智药生物技术有限公司、上海国盛资本管理有限公司-上海国盛海通股权投资基金 合伙企业(有限合伙)、贵阳开元生物资源开发有限公司、中国建设银行股份有限公司-诺安多策略股票型 证券投资基金、UBS AG、金元顺安鑫怡混合发起式A，机构投资者合计持股比例达33.51%。相较于上 一季度，机构持股比例合计下跌了1.07个百分点。 外资态度来看，本期较上一季度新披露的外资机构有 1 家 ，即UBS AG。 公募基金方面，本期较上一季度新披露的公募基金共计2个，包括诺安多策略混合A、金元顺安鑫怡混 合发起式A。本期较上一季未再披露的公募基金共计1个，即博道远航混合A。 ...

Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 358 million yuan, representing a year-on-year decrease of 18.88% [1] - The net profit attributable to shareholders of the listed company was 5.77 million yuan, down 80.99% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 3.58 million yuan, reflecting a year-on-year decline of 87.87% [1] - The basic earnings per share were reported at 0.0236 yuan [1]

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. reported a significant decline in revenue and net profit for the first half of 2025, with a focus on its core business of traditional Chinese medicine and a commitment to innovation and quality in its product offerings [1][2]. Company Overview and Financial Indicators - The company reported operating revenue of CNY 358.29 million, a decrease of 18.88% compared to CNY 441.70 million in the same period last year [2]. - The net profit attributable to shareholders was CNY 5.77 million, down 80.99% from CNY 30.34 million year-on-year [2]. - The basic earnings per share fell to CNY 0.0236, a decline of 82.01% from CNY 0.1312 [2]. - Total assets decreased by 3.41% to CNY 1.88 billion, while net assets attributable to shareholders decreased by 0.70% to CNY 1.19 billion [2]. Business Operations - The company specializes in the research, development, production, and sales of traditional Chinese medicine, focusing on gynecological and urological medications [3][4]. - It has a diverse product line, including 12 unique products, with a strong emphasis on proprietary formulations that address specific health issues [3][4]. - The company has established a comprehensive R&D platform covering the entire lifecycle of traditional Chinese medicine, integrating modern technology with traditional practices [6][14]. Product Highlights - Key products include Kun Tai Capsules, Ning Pi Tai Capsules, and Ku Shen Gel, all of which are recognized for their clinical efficacy and have received various accolades in the market [4][11]. - Kun Tai Capsules are particularly noted for their effectiveness in treating ovarian function decline and have been included in several clinical guidelines [4][11]. - Ning Pi Tai Capsules have gained recognition in the treatment of urinary tract infections and chronic prostatitis, showcasing the company's commitment to addressing prevalent health issues [4][11]. Market Strategy and Competitive Advantage - The company employs a professional marketing strategy that emphasizes clinical efficacy and product quality, aiming to build trust among healthcare professionals and patients [10][11]. - It has a strong focus on innovation, with ongoing research into new drug formulations and enhancements to existing products, ensuring a robust pipeline for future growth [14][15]. - The strategic location in Guizhou province provides access to a rich variety of medicinal herbs, enhancing the company's competitive edge in sourcing high-quality raw materials [13]. Financial Management and Cost Control - The company has implemented stringent cost control measures, resulting in a reduction in operating costs and expenses, including a decrease in sales and management expenses [16]. - Research and development expenditures were reduced by 26.38% to CNY 22.82 million, reflecting a strategic shift in resource allocation [16]. - The company reported a significant improvement in cash flow from operating activities, with a net cash flow increase of 106.93% compared to the previous year [2].

| 贵阳新天药业股份有限公司 | | | 2025 年半年度报告摘要 | | --- | --- | --- | --- | | 证券代码：002873 证券简称：新天药业 | | | 公告编号：2025- | | 046 | | | | | 贵阳新天药业股份有限公司 | | | | | 一、重要提示 | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | | 资者应当到证监 | | | | | 会指定媒体仔细阅读半年度报告全文。 | | | | | 所有董事均已出席了审议本报告的董事会会议。 | | | | | 非标准审计意见提示 | | | | | □适用 ?不适用 | | | | | 董事会审议的报告期利润分配预案或公积金转增股本预案 | | | | | □适用 ?不适用 | | | | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | | | | | 董事会决议通过的本报告期优先股利润分配预案 | | | | | □适用 ?不适用 | | | | | 二、公司基本情况 | | | | | 股票简称 | 新天药业 | ...

新天药业2025半年报 ...

证券日报网讯 7月30日晚间，新天药业发布公告称，本公司近日收到控股股东上海新天智药生物技术有 限公司（简称"新天智药"）的通知，新天智药对其部分已质押股份办理了解除质押手续，解除质押股份 数量为3，170，000股。 （文章来源：证券日报） ...

经济观察网 7月30日，新天药业(002873.SZ)发布2025年半年度报告，该公司营业收入为3.58亿元，同比 减少18.88%。归属于上市公司股东的净利润为576.61万元，同比减少80.99%。归属于上市公司股东的扣 除非经常性损益的净利润为357.95万元，同比减少87.87%。基本每股收益为0.0236元。 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-047 注：公司上述股份办理质押时，质权人为海通证券股份有限公司，现因该公司合并 等原因，已更名为国泰海通证券股份有限公司。 二、股东股份累计被质押的情况 1 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"或"本公司"）近日收到控 股股东上海新天智药生物技术有限公司（以下简称"新天智药"）的通知，新天 智药对其部分已质押股份办理了解除质押手续，具体情况如下： | 股东 | 是否为 控股股 东及其 | 本次解除 质押股份 | 占其所持 | 占公司 总股本 | 质押 | 质押 | 解除质 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | 股份比例 | | 开始日 | 到期日 | 押日 | | | | 一致行 | 数量（股） | | 比例 | | | | | | | 动人 | | | | | | | | | 新天 | 是 | 3,170,000 | 4.20% ...

新天药业（002873）公告，控股股东新天智药近日对其部分已质押股份办理了解除质押手续，解除质押 股份数量为317万股，占其所持股份比例4.20%，占公司总股本比例1.30%。本次解质押后，新天智药累 计质押股份数量为4879.68万股，占其所持股份比例64.64%，占公司总股本比例19.99%。新天智药本次 解除股份质押不涉及新增融资安排，所质押股份不存在平仓风险。 ...

Group 1 - The core viewpoint of the article is that Xintian Pharmaceutical (002873.SZ) reported a significant decline in both revenue and net profit for the first half of 2025 [1] Group 2 - The company achieved operating revenue of 358 million yuan, representing a year-on-year decrease of 18.88% [1] - The net profit attributable to shareholders of the listed company was 5.7661 million yuan, down 80.99% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 3.5795 million yuan, a decrease of 87.87% year-on-year [1] - The basic earnings per share were 0.0236 yuan [1]